Skip to main content
Evidence & recognition

MediBioSense are pleased to announce they are part of a successful consortium in receiving €42 million H2020 EU funding.

MediBioSense are pleased to announce they are part of a successful consortium in receiving €42 million H2020 EU funding.

MediBioSense will be providing healthcare wearable technologies as part of the project.

The European research project is to Identify Digital Endpoints to Assess FAtigue, Sleep and acTivities of daily living (acronym: IDEA-FAST) in the following neurodegenerative disorders (NDD): Parkinson’s disease and Huntington’s disease and in the following immune-mediated inflammatory diseases (IMID): Rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren’s syndrome, and inflammatory bowel disease.

This is an archived announcement, preserved as originally published on . Product names, certifications and partnerships may have changed since. See Solutions for the current range.

Every pathway. Every patient. Every service is different.

Tell us what you’re trying to achieve and we’ll tell you honestly whether MediBioSense is the right fit — and what it would take to run a successful pilot.

info@medibiosense.com Start a conversation

Talk directly to the people who build, develop and deploy the technology.